“…As to hsa-miR-193a-5p in other cancers, there have been a lots of special research reports, like, on ovarian cancer, [75,76] on lung cancer, [77,78] on breast cancer [79][80][81][82] on melanoma, [83] on hepatoblastoma, [84] on esophageal squamous cell carcinoma, [85] on gastric cancer, [86,87] on rhabdomyosarcoma, [88] on papillary thyroid carcinoma, [89] on colorectal cancer, [90][91][92][93][94][95] on cervical cancer, [96,97] on nasopharyngeal carcinoma, [98] on acute myeloid leukemia, [99] on clear-cell renal cell carcinoma, [100] on pancreatic cancer, [101,102] on glioma, [103] on pediatric chordomas, [104] on bladder cancers, [105] on osteosarcoma, [106,107] on prostate cancer, [108][109][110] and on HCC. [111][112][113] Among those special research reports on non-EC cancers, most showed that the effects of hsa-miR-193a-5p on the relative cancers were negatively oncogenic, as hsa-miR-193a-5p was a potential tumor suppressor. [75][76][77][78]…”